| |DECEMBER 20248BLOCKCHAIN AND IOT REVOLUTIONIZE THE CLINICAL TRIAL SUPPLIES MARKETThe arrival of nafithromycin, the nation's initial homegrown macrolide antibiotic currently waiting for final endorsement from the Central Drugs Standard Control Organization (CDSCO), will mark a crucial moment in the battle against antimicrobial resistance, highlighting India's expanding expertise in pharmaceutical innovation, according to the ministry of chemicals and fertilizers.The medication created with Rs. On November 20, 2024, Union minister Dr. Jitendra Singh officially launched the Biotechnology Industry Research Assistance Council (BIRAC) Biotech Industry Programme, which includes funding of 8 crore for phase 3 clinical trials.Created by Wockhardt with assistance from BIRAC, the medication will be sold under the name "Miqnaf," aiming at community-acquired bacterial pneumonia (CABP) due to drug-resistant bacteria, which mainly impacts vulnerable groups like children, the elderly, and individuals with weakened immune systems.This innovative antibiotic is ten times more potent than existing therapies such as azithromycin and provides a three-day treatment course, greatly reducing recovery time while enhancing patient results. Nafithromycin is developed to target both standard and unusual drug-resistant bacteria, positioning it as an essential resource in combating the worldwide health challenge of AMR (anti-microbial resistance). "It offers enhanced safety, reduced side effects, and no major drug interactions," stated the ministry. POThe Clinical Trial Supplies market is driven by advanced technologies like blockchain and IoT in supply chain management. The market is projected to increase from US$2.70 Bn in 2024 to US$4.79 Bn by 2033, achieving a CAGR of 6.58 percent throughout the forecast period spanning from 2025 to 2033.The primary factors propelling the expansion of the clinical trial supplies market are chronic illnesses like cancer, diabetes, and heart disease. As the occurrence of these diseases grows, the likelihood of discovering new treatments and therapies rises, leading to a boost in clinical trials. For these trials, a diverse range of supplies might be required, including experimental drugs, testing kits, and medical equipment. Therefore, the need for these clinical trial supplies rises as well. The increasing importance of personalized medicine in chronic diseases enhances the need for particular trial supplies.Stricter regulations globally are forcing the clinical trial supplies market to expand. Western governments and regulatory agencies, such as the FDA and EMA, have become more stringent regarding clinical trials, which must ensure safety, efficacy, and transparency. It requires that clinical trial supplies adhere to strictly regulated quality control, packaging, and labeling criteria, thus raising the demand for dependable and compliant trial materials. With the improvement of regulations, the realm of clinical trial supplies is expanding to meet the greater demands for ensuring trial success. POTOP STORIESINDIA'S INDIGENOUS ANTIBIOTIC TO COMBAT AMR HIGHLIGHTS PHARMA PROGRESS
< Page 7 | Page 9 >